EUROPEAN COMMISSION APPROVES KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AS PERIOPERATIVE TREATMENT FOR ADULTS WITH RESECTABLE MUSCLE-INVASIVE BLADDER CANCER (MIBC)

Reuters · 3d ago

Please log in to view news